[KSCI] Korea Science Citation Index Service

http://dx.doi.org/10.22643/JRMP.2019.5.2.152

Development of radiotracer for polo-box domain of polo-like kinase 1

Ryu, Eun Kyoung (Research Center for Bioconvergence Analysis, Korea Basic Science Institute, University of Science and Technology)

Publication Information

Journal of Radiopharmaceuticals and Molecular Probes / v.5, no.2, 2019 , pp. 152-157 More about this Journal

Abstract

Polo-like kinase 1 (Plk1) is crucial regulator of cell cycle progression during mitosis. It is known to highly overexpress in many different tumor types, and has been implicated as a potential antimitotic cancer target. The phosphopeptide, Pro-Leu-His-Ser-p-Thr (PLHSpT), was shown a high level of affinity and specificity for the polo-box domain (PBD) of Plk1. However, the peptide has the limitation of cell permeability. We designed the derivatives to enhance the limitation of PLHSpT using drug delivery system. In addition, we synthesized and evaluated its radiotracer for tumor diagnosis. This review discusses the derivative and radiotracer that are suitable for tumor treatment and diagnosis for PBD of Plk1.

Keywords

Polo-like kinase 1; Polo-box domain; PLHSpT; Radiotracer; Tumor; Treatment; Diagnosis;

Citations & Related Records

Times Cited By KSCI : 1 (Citation Analysis)

Reference
Cited By KSCI

1	Vaupel P and A Mayer, Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007; 26(2): p. 225-39. DOI
2	Kim SM, S Yoon, N Choi, KS Hong, RN Murugan, G Cho, and EK Ryu, In vivo tumor imaging using polobox domain of polo-like kinase 1 targeted peptide. Biomaterials 2012; 33(29): p. 6915-25. DOI
3	Yang C, T Wu, Y Qi, and Z Zhang, Recent Advances in the Application of Vitamin E TPGS for Drug Delivery. Theranostics 2018; 8(2): p. 464-485. DOI
4	Cao N and SS Feng, Doxorubicin conjugated to D-alphatocopheryl polyethylene glycol 1000 succinate (TPGS): conjugation chemistry, characterization, in vitro and in vivo evaluation. Biomaterials 2008; 29(28): p. 3856-65. DOI
5	Dietrich M, MG Traber, PF Jacques, CE Cross, Y Hu, and G Block, Does gamma-tocopherol play a role in the primary prevention of heart disease and cancer? A review. J Am Coll Nutr 2006; 25(4): p. 292-9. DOI
6	Yim MS, NK Soung, EH Han, JY Min, H Han, EJ Son, HN Kim, B Kim, JK Bang, and EK Ryu, Vitamin E-Conjugated Phosphopeptide Inhibitor of the Polo-Box Domain of Polo-Like Kinase 1. Mol Pharm 2019.
7	Khramtsov VV and RJ Gillies, Janus-faced tumor microenvironment and redox. Antioxid Redox Signal 2014; 21(5): p. 723-9. DOI
8	Holtrich U, G Wolf, A Brauninger, T Karn, B Bohme, H Rubsamen-Waigmann, and K Strebhardt, Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors. Proc Natl Acad Sci U S A 1994; 91(5): p. 1736-40. DOI
9	Glover DM, IM Hagan, and AA Tavares, Polo-like kinases: a team that plays throughout mitosis. Genes Dev 1998; 12(24): p. 3777-87. DOI
10	van de Weerdt BC and RH Medema, Polo-like kinases: a team in control of the division. Cell Cycle 2006; 5(8): p. 853-64. DOI
11	Simizu S and H Osada, Mutations in the Plk gene lead to instability of Plk protein in human tumour cell lines. Nat Cell Biol 2000; 2(11): p. 852-4. DOI
12	Lee KS, JE Park, YH Kang, TS Kim, and JK Bang, Mechanisms underlying Plk1 polo-box domain-mediated biological processes and their physiological significance. Mol Cells 2014; 37(4): p. 286-94. DOI
13	Liu X, M Lei, and RL Erikson, Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol Cell Biol 2006; 26(6): p. 2093-108. DOI
14	McInnes C, M Mezna, and PM Fischer, Progress in the discovery of polo-like kinase inhibitors. Curr Top Med Chem 2005; 5(2): p. 181-97. DOI
15	Baby B, P Antony, W Al Halabi, Z Al Homedi, and R Vijayan, Structural insights into the polypharmacological activity of quercetin on serine/threonine kinases. Drug Des Devel Ther 2016; 10: p. 3109-3123. DOI
16	Guan R, P Tapang, JD Leverson, D Albert, VL Giranda, and Y Luo, Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals. Cancer Res 2005; 65(7): p. 2698-704. DOI
17	Yun SM, T Moulaei, D Lim, JK Bang, JE Park, SR Shenoy, F Liu, YH Kang, C Liao, NK Soung, S Lee, DY Yoon, Y Lim, DH Lee, A Otaka, E Appella, JB McMahon, MC Nicklaus, TR Burke, Jr., MB Yaffe, A Wlodawer, and KS Lee, Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of pololike kinase 1. Nat Struct Mol Biol 2009; 16(8): p. 876-82. DOI
18	Cho K, X Wang, S Nie, ZG Chen, and DM Shin, Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008; 14(5): p. 1310-6. DOI
19	Danhier F, O Feron, and V Preat, To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 2010; 148(2): p. 135-46. DOI
20	Torchilin V, Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev 2011; 63(3): p. 131-5. DOI
21	Gillies RJ, N Raghunand, ML Garcia-Martin, and RA Gatenby, pH imaging. A review of pH measurement methods and applications in cancers. IEEE Eng Med Biol Mag 2004; 23(5): p. 57-64.